Publication:
Impact of Epstein-Barr virus infection on inflammatory bowel disease clinical outcomes

No Thumbnail Available

Date

2022-01-01

Authors

Nunez Ortiz, Andrea
Rojas Feria, Maria
de la Cruz Ramirez, Maria Dolores
Gomez Izquierdo, Lourdes
Trigo Salado, Claudio
Herrera Justiniano, Jose Manuel
Leo Carnerero, Eduardo

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Aran ediciones, s a
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Objective: to evaluate the role of Epstein-Barr virus (EBV) on the intestinal mucosa in the evolution of inflammatory bowel disease (IBD). The risk factors for EBV infection and the frequency of EBV-associated lymphoproliferative disorders in IBD patients were also investigated.Methods: intestinal biopsies of IBD patients with available EBV status determined by Epstein-Barr-encoding RNA (EBER) in situ hybridization were identified in the Pathology Database of our center. Clinical information, including phenotypic characteristics of IBD, previous treatments, diagnosis of lymphoma and patient outcome were reviewed in all cases.Results: fifty-six patients with IBD (28 Crohn's disease, 27 ulcerative colitis and one unclassified colitis) were included. EBV in intestinal mucosa was positive in 26 patients (46 %) and was associated to a lymphoproliferative syndrome in one case. EBV positivity was associated with severe histological activity (52 % vs 17.2 %; p 0.007), the presence of a lymphoplasmacytic infiltrate (50 % vs 33.3 %; p 0.03) and active steroid treatment (61.5 % vs 33.3 %; p 0.03). Multi-variate analyses only found an association between EBV and lymphoplasmacytosis (p 0.001). Escalation in previous treatment was significantly more frequent in the EBER+ group (53.8 % vs 26.7 %; p 0.038). No cases developed lymphoma during follow-up.Conclusions: EBV on the intestinal mucosa is associated with a poor outcome of IBD and the need for escalation of therapy. Lymphoplasmacytic infiltrate is associated with EBV infection. EBER+ patients used steroids more frequently compared with EBER- patients. No EBER+ patients developed lymphoma during follow-up.

Description

MeSH Terms

DeCS Terms

CIE Terms

Keywords

Inflammatory bowel disease, Epstein-Barr virus, Lymphoplasmacytosis, lmmunosuppressants, EBER in situ hybridization, Human cytomegalovirus, Colon, Cells

Citation